文献速递肝病

荷兰原发性胆汁性胆管炎全国队列抗胆汁淤积治疗使用评估

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation.
PubMed 文献 · Aliment Pharmacol Ther · 2026-04-14

该回顾性全国队列纳入1990年起荷兰可识别的2638例PBC患者,评估2019年1月1日在随访中患者的UDCA及二线治疗使用情况。96.0%患者使用UDCA,但仅61.8%达到推荐剂量≥13 mg/kg/day;应答不完全者中15.8%接受二线治疗。结果表明UDCA剂量不足,一线治疗有待优化。

要点

  • 96.0%的PBC患者使用UDCA,但仅61.8%达到推荐剂量≥13 mg/kg/day
  • 生化应答者及体重较高者更易出现UDCA剂量不足
  • 应答不完全者中仅15.8%接受二线治疗

核心结论

  • 荷兰PBC患者中UDCA剂量不足常见,一线治疗存在优化空间,尤其对生化应答者和体重较高者。

研究设计与样本

  • 荷兰PBC队列研究为回顾性研究,纳入1990年起荷兰所有可识别的PBC患者,评估2019年1月1日在临床随访中患者的UDCA及二线治疗使用情况。

主要发现

  • 共纳入2638例PBC患者,中位年龄64.0岁(IQR 55.0-72.0),女性2361例(89.5%),2143例(81.2%)在非学术中心治疗。
  • 2532例(96.0%)使用UDCA,其中1363/2205例(61.8%)使用推荐剂量≥13 mg/kg/day。
  • 年龄(aOR 1.01,95%CI 1.00-1.02,p=0.02)、体重(aOR 1.04,95%CI 1.03-1.05,p<0.01)和生化应答(aOR 1.35,95%CI 1.09-1.67,p=0.01)与UDCA剂量<13 mg/kg/day相关。
  • 应答不完全患者中,101/638例(15.8%)接受二线治疗;年轻、女性、学术中心治疗及较高ALP和AST水平与二线治疗使用正相关。

关键数值与推荐

  • 生化应答定义为碱性磷酸酶(ALP)和天冬氨酸氨基转移酶(AST)≤1.5×ULN且总胆红素(TB)≤ULN。
  • UDCA推荐剂量为≥13 mg/kg/day。
  • 二线治疗包括超说明书使用的贝特类、布地奈德和/或奥贝胆酸(未报销)。

临床怎么用

  • 临床应关注PBC患者UDCA剂量是否达到≥13 mg/kg/day,尤其对生化应答者和体重较高者。
  • 对应答不完全者,需评估是否及时启用二线治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Optimal care delivery for primary biliary cholangitis (PBC) has become challenging due to new therapies and more individualized biochemical treatment goals. AIM: To evaluate uptake of ursodeoxycholic acid (UDCA) and second-line therapy (SLT) in a nationwide PBC cohort and identify factors associated with suboptimal therapeutical management. METHODS: The Dutch PBC Cohort Study is a retrospective study including every identifiable patient with PBC in the Netherlands from 1990 onwards. Use of UDCA and SLT was assessed among patients in clinical follow-up on 1 January 2019. Biochemical response was defined as alkaline phosphatase (ALP) and aspartate aminotransferase (AST) ≤ 1.5 × ULN and total bilirubin (TB) ≤ ULN. SLT included off-label fibrates, budesonide and/or obeticholic acid (not reimbursed). RESULTS: In total, 2638 patients with PBC were included; median age was 64.0 (IQR 55.0-72.0) years, 2361 (89.5%) were female and 2143 (81.2%) were treated in a non-academic center. Overall, 2532 (96.0%) patients used UDCA. The recommended UDCA dose of ≥ 13 mg/kg/day was used by 1363/2205 (61.8%). Age (aOR 1.01, 95% CI 1.00-1.02, p = 0.02), body weight (aOR 1.04, 95% CI 1.03-1.05, p < 0.01) and biochemical response (aOR 1.35, 95% CI 1.09-1.67, p = 0.01) were associated with UDCA dosage < 13 mg/kg/day. Among patients with an incomplete response, 101/638 (15.8%) were prescribed SLT. Younger age, female sex, treatment in an academic centre and higher levels of ALP and AST were positively associated with use of SLT. CONCLUSIONS: During recent years, UDCA was insufficiently dosed in Dutch patients with PBC. The results indicate that first-line treatment can be optimized, especially in those with a biochemical response and higher body weight.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Werner E, van Hooff MCB, Weijsters GHX, et al. A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation. Aliment Pharmacol Ther. 2026. PMID: 41979410. doi:10.1111/apt.70669

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。